Athersys, Inc. Reports First Quarter 2013 Results
5/15/2013 9:33:00 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
CLEVELAND, May 14, 2013 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) today announced its financial results for the three months ended March 31, 2013. "Our focus remains on the advancement of our lead clinical programs, MultiStem for ulcerative colitis with our partner, Pfizer, and MultiStem for ischemic stroke, and on the development of new business collaboration opportunities," said Gil Van Bokkelen, Ph.D., Chairman and Chief Executive Officer. "We are also engaged in preparations for the next stage of MultiStem clinical development, including planning and development to support manufacturing scale-up. As a result, we should be well placed to move forward productively and efficiently following achievement of our current objectives."
Help employers find you! Check out all the jobs and post your resume.
comments powered by